The company’s decision to scrap the deal comes after it pulled the plug on an early-stage study in August last year that was testing lemzoparlimab in combination with two other drugs for treating two types of blood cancers, myelodysplastic syndrome and acute myelocytic leukemia.

The company declined to exercise the license option for Harpoon Therapeutics’ TriTAC HPN217 program for multiple myeloma, which targets B cell maturation antigen, or BCMA.

Continuing its clinical win streak, AbbVie’s Skyrizi showed signs of superiority against Johnson & Johnson’s Stelara in topline data from a head-to-head Phase III Crohn’s disease study.

As biosimilars and other next-generation treatments for Crohn’s disease enter the market, AbbVie will be knocked from its place of longtime dominance.

The approval by the Food and Drug Administration helps Revance enter the $2.5 billion U.S. market for therapeutic neuromodulator, a method that directly acts on nerves, the company said on Monday.

It’s summer 2023. By now, many of us have “emerged”, as they say. We are getting out and about and making up for the lost time of the past three years. And much of this progress is thanks to the COVID-19 vaccines and treatments from Pfizer, BioNTech, and Moderna, which played a major role in helping us put the pandemic in the rearview mirror.

With funding and business-friendly incentives more challenging to come by in constricting Western economies, some life sciences companies partner with Middle Eastern governments, which are rolling out the red carpet.

The company cited $280 million in milestone and in-process research and development expenses during the second quarter.

Mark Cuban Cost Plus Drugs, an online pharmacy launched by the billionaire to sell drugs directly to customers at low prices, should soon begin selling Coherus BioSciences’s biosimilar version of AbbVie’s blockbuster rheumatoid arthritis drug Humira, Cuban said yesterday.

The copycat drug was launched at about a 5% discount, adding to the growing competition for the blockbuster rheumatoid arthritis drug in the U.S.